Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Lo-Coco

Showing results (1-10 of 265) with videos related to

Pageof 27
Sort By:
Haematologica|March 8, 2005
Additive effects in the induction of apoptosis in leukemic cells by WT1 and BCR-ABL specific siRNAFrancesco Lo Coco
International Journal of Hematologic Oncology|October 11, 2018
Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-CocoFrancesco Lo-Coco
Blood|August 6, 2011
ED in APL: tip of the iceberg?Francesco Lo-Coco
Haematologica|May 16, 2002
Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemiaFrancesco Lo Coco
Expert Opinion on Biological Therapy|December 15, 2010
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacyMassimo Breccia, Francesco Lo-Coco
Annals of Hematology|February 28, 2016
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patientsUgo Testa, Francesco Lo-Coco
The Lancet. Oncology|June 10, 2018
Towards home-based treatment for acute promyelocytic leukaemia, with cautionFrancesco Lo-Coco, Laura Cicconi
Mediterranean Journal of Hematology and Infectious Diseases|January 6, 2012
History of acute promyelocytic leukemia: a tale of endless revolutionFrancesco Lo-Coco, Laura Cicconi
Expert Opinion on Pharmacotherapy|April 4, 2012
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent diseaseMassimo Breccia, Francesco Lo-Coco
Stem Cell Investigation|July 1, 2016
Targeting of leukemia-initiating cells in acute promyelocytic leukemiaUgo Testa, Francesco Lo-Coco
Pageof 27

Showing results (1-10 of 265) with videos related to

Sort By:
Pageof 27
Haematologica|March 8, 2005
Additive effects in the induction of apoptosis in leukemic cells by WT1 and BCR-ABL specific siRNAFrancesco Lo Coco
International Journal of Hematologic Oncology|October 11, 2018
Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-CocoFrancesco Lo-Coco
Blood|August 6, 2011
ED in APL: tip of the iceberg?Francesco Lo-Coco
Haematologica|May 16, 2002
Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemiaFrancesco Lo Coco
Expert Opinion on Biological Therapy|December 15, 2010
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacyMassimo Breccia, Francesco Lo-Coco
Annals of Hematology|February 28, 2016
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patientsUgo Testa, Francesco Lo-Coco
The Lancet. Oncology|June 10, 2018
Towards home-based treatment for acute promyelocytic leukaemia, with cautionFrancesco Lo-Coco, Laura Cicconi
Mediterranean Journal of Hematology and Infectious Diseases|January 6, 2012
History of acute promyelocytic leukemia: a tale of endless revolutionFrancesco Lo-Coco, Laura Cicconi
Expert Opinion on Pharmacotherapy|April 4, 2012
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent diseaseMassimo Breccia, Francesco Lo-Coco
Stem Cell Investigation|July 1, 2016
Targeting of leukemia-initiating cells in acute promyelocytic leukemiaUgo Testa, Francesco Lo-Coco
Pageof 27